These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 24346851)
21. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. Salgado BJ; Salgado JV; Dos Santos AM; Casulari LA Minerva Cardioangiol; 2010 Oct; 58(5):531-42. PubMed ID: 20948500 [TBL] [Abstract][Full Text] [Related]
22. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers. Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703 [TBL] [Abstract][Full Text] [Related]
23. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888 [TBL] [Abstract][Full Text] [Related]
24. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin. Pandian A; Arora A; Sperling LS; Khan BV Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748 [TBL] [Abstract][Full Text] [Related]
25. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Guyton JR; Fazio S; Adewale AJ; Jensen E; Tomassini JE; Shah A; Tershakovec AM Diabetes Care; 2012 Apr; 35(4):857-60. PubMed ID: 22338103 [TBL] [Abstract][Full Text] [Related]
26. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Bogman K; Brumm J; Hofmann C; Giraudon M; Niggli M; Sturm-Pellanda C; Sauter A; Sturm S; Mangold B; Schmitt C Clin Pharmacokinet; 2019 Sep; 58(9):1205-1214. PubMed ID: 30968335 [TBL] [Abstract][Full Text] [Related]
27. Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets. Milanowski B; Hejduk A; Bawiec MA; Jakubowska E; Urbańska A; Wiśniewska A; Garbacz G; Lulek J AAPS PharmSciTech; 2020 Jan; 21(3):83. PubMed ID: 31989330 [TBL] [Abstract][Full Text] [Related]
28. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan. Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562 [TBL] [Abstract][Full Text] [Related]
29. Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.). Milionis HJ; Elisaf MS Am Heart J; 2005 Jul; 150(1):e7. PubMed ID: 16084140 [No Abstract] [Full Text] [Related]
30. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. Darwish M; Bond M; Tracewell W; Robertson P; Yang R Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549 [TBL] [Abstract][Full Text] [Related]
31. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632 [TBL] [Abstract][Full Text] [Related]
32. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Bays HE; McGovern ME Prev Cardiol; 2005; 8(4):226-33. PubMed ID: 16230877 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. Michailov GV; Davies GM; Krobot KJ Eur J Health Econ; 2012 Jun; 13(3):365-74. PubMed ID: 21465286 [TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243 [TBL] [Abstract][Full Text] [Related]
35. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. AIM-HIGH Investigators Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609 [TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390 [TBL] [Abstract][Full Text] [Related]
37. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Airan-Javia SL; Wolf RL; Wolfe ML; Tadesse M; Mohler E; Reilly MP Am Heart J; 2009 Apr; 157(4):687.e1-8. PubMed ID: 19332196 [TBL] [Abstract][Full Text] [Related]
38. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Rubenfire M; Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Sunkara G; Reynolds CV; Pommier F; Humbert H; Yeh C; Prasad P Curr Med Res Opin; 2007 Mar; 23(3):631-40. PubMed ID: 17355744 [TBL] [Abstract][Full Text] [Related]
40. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. HPS2-THRIVE Collaborative Group Eur Heart J; 2013 May; 34(17):1279-91. PubMed ID: 23444397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]